glp 1 and gip combination The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review The Novel Dual GIP and

GLP-1 medications can reduce appetite, which may lead to inadequate protein intake and potential muscle loss

Behavioral factors also contribute, as people gradually return to larger portions or less disciplined food choices as the "novelty" of appetite suppression fades

For this reason, Healthspan pairs the Wegovy pill with clinician-guided dosing, side-effect management, and ongoing support to ensure the therapy is used safely and effectively over time

Moreover, in light of the growing evidence demonstrating the benefits of incretin-based therapies on both metabolic health and cardiovascular diseases, regulatory agencies such as the Food Drug Administration (FDA) and the European Medicines Agency (EMA) have approved their use for type 2 diabetes, reduction of cardiovascular risk and for chronic weight management in patients with morbid obesity [58]